Drug profile · INN
teplizumab
TEIZEILD
teplizumab (TEIZEILD) is a t-cell surface glycoprotein cd3 epsilon chain other.
EMA: approved NMPA: clinical trials Alimentary tract and metabolism (A10) A10XX01
Patents linked 0
Pipeline programs 2
News articles 1
Drug details — teplizumab
- Class
- Alimentary tract and metabolism (A10)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
teplizumab (TEIZEILD) is a t-cell surface glycoprotein cd3 epsilon chain other.
Key facts
INN teplizumab
Brand TEIZEILD
Mechanism T-cell surface glycoprotein CD3 epsilon chain other
Target T-cell surface glycoprotein CD3 epsilon chain
Therapeutic class Alimentary tract and metabolism (A10)
ATC code A10XX01
Mechanism of action
T-cell surface glycoprotein CD3 epsilon chain other
Primary target: T-cell surface glycoprotein CD3 epsilon chain
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is teplizumab?
teplizumab (TEIZEILD) is a t-cell surface glycoprotein cd3 epsilon chain other.
What is the brand name for teplizumab?
TEIZEILD is a marketed brand name for teplizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.